- Zymergen uses a combination of robots and proprietary software to build and test thousands of new strains of DNA at a time, accomplishing in a matter of days what the company says might ordinarily take postdoctoral researchers in a lab around a year.
- The Zymergen pitch is that not only is the company cutting down on labor costs by automating experiments, its data-intensive, machine learning technology gets better over time, refining the process and working out the kinks.
- Hoffman says the two year-old company plans to use the money to go after new talent and to help scale the platform. As for what’s next, he said “an IPO is in the cards,” but first they have to get through spending all this new money.
Synthetic Biology Startup Zymergen Emerges From Stealth With $44 Million
6. 29. 15 by Jim Crawford